Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer
Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma
(HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis
and outcome for patients who have undergone surgical removal of the cancer. In such ...
Age: 18 years - 66+
Gender: All
A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
This trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual
CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma.
Age: 18 years - 66+
Gender: All
The Ambient Light Multiple Myeloma Study
The aim of this multi-site randomized control trial will be is to assess the impact
Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and
Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell
Transplantat...
Age: 21 years - 66+
Gender: All
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy
(SG) in combination with pembrolizumab given after surgery, is effective and safe compared to
the treatment of physician's choice (TPC) which includes either pembrolizumab ...
Age: 18 years - 66+
Gender: All
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
The main purpose of this study is to learn more about the safety, side effects, and
effectiveness of LOXO-435. LOXO-435 may be used to treat cancer of the cells that line the
urinary system and other solid tumor cancers that have a change in a particular gene (known...
Age: 18 years - 66+
Gender: All
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course
chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs,
such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX
...
Age: 18 years - 66+
Gender: All
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety,
tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination
with balstilimab or standard-of-care treatments in participants with refractory metastati...
Age: 18 years - 66+
Gender: All
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study are to test for any side effects from modakafusp alfa in
combination therapy and to determine the recommended dose of combination therapy with
modakafusp. The dose of modakafusp alfa will be increased a little at a time until the
highes...
Age: 18 years - 66+
Gender: All
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial evaluates nilotinib with paclitaxel for the
treatment of patients with solid cancers that are growing, spreading, or getting worse
(progressive) and that have previously been treated with taxane therapies. Nilotinib is in a
...
Age: 18 years - 66+
Gender: All
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy
(paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be
removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally
advance...
Age: 18 years - 66+
Gender: All
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as
monotherapy or in combination with ultralow dose gemcitabine in participants with
platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma
ba...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in
participants with refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Age: 18 years - 66+
Gender: All
Phase 1b Combo w/ Ribociclib and Alpelisib
This is a Phase 1b open-label, 2-part study in 2 treatment groups. The 2 treatment groups are
as follows:
Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals
Corporation).
Treatment Group 2: OP-1250 in combination wi...
Age: 18 years - 66+
Gender: All
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
This is a phase I, open label study employing diphencyprone (DPCP) to characterize gene
expression changes of various immune cell and tumor markers in cutaneous metastases treated
with topical DPCP twice weekly for 12 weeks in combination with PD-1 or PD-L1 immune
...
Age: 18 years - 66+
Gender: All
Phase 2 Study of DKN-01 in Colorectal Cancer
This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to
evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of
care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanc...
Age: 18 years - 66+
Gender: All
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose
(RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with
investigator-selected standard of care (SoC) therapy in Part 2 in subjects with inoperabl...
Age: 18 years - 66+
Gender: All
Intestinal Microbiome, Oral Microbiome, and Whole Blood Transcriptome Analyses in Gastrointestinal Malignancies
The primary objective of this prospective observational study is to characterize the gut and
oral microbiome as well as the whole blood transcriptome in gastrointestinal cancer patients
and correlate these findings with cancer type, treatment efficacy and toxicity.
Age: 18 years - 66+
Gender: All
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following
chemotherapy for the treatment of surgically resectable pancreatic cancer.
Age: 19 years - 66+
Gender: All
A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery
This study is open to people with newly diagnosed colorectal cancer. People who are scheduled
for surgery can participate. People either get a medicine called BI 765063 combined with
ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. ...
Age: 18 years - 66+
Gender: All